Navigation Links
Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008

BURLINGTON, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, today announced financial results for the fourth quarter and year ended December 31, 2008. Revenues for the quarter ended December 31, 2008 were $17.2 million, of which $13.3 million were product revenues, $2.2 million were royalty revenues, $0.5 million were funded development revenues, and $1.25 million were other revenues. Fourth quarter gross margin from product revenues was 58 percent. Loss before taxes for the fourth quarter ended December 31, 2008 was $0.6 million, which included approximately $0.6 million in litigation expenses and a $0.8 million non-cash FAS 123R stock-based compensation expense.

Revenues for the year ended December 31, 2008 were $87.6 million, of which $69.4 million were product revenues, $10.5 million were royalty revenues, $2.4 million were funded development revenues, and $5.3 million were other revenues. Gross margin from product revenues was 64 percent for the year ended December 31, 2008. Loss before taxes for the year ended December 31, 2008 was $0.1 million, which included approximately $9.4 million in litigation expenses and a $5.9 million non-cash FAS 123R stock-based compensation expense.

The Company reported net loss of $0.4 million, or $0.02 per diluted share for the fourth quarter of 2008 and net loss of $68,000, or $0.00 per diluted share for the year ended December 31, 2008. Non-GAAP net income for the quarter ended December 31, 2008, which includes adjustments for the non-cash FAS 123R compensation expense and non-cash taxes, resulted in $0.2 million, or $0.01 per diluted share. Non-GAAP net income for the year ended December 31, 2008, which includes adjustments for back-owed royalties, trade dress infringement fees, cost of back-owed royalty revenues, investment banking fees related to an international distributor agreement, non-cash FAS 123R compensation expense, interest on back-owed royalties, and non-cash taxes, resulted in $5.9 million, or $0.32 per diluted share. Please refer to the financial statements included in this news release for a reconciliation of GAAP to non-GAAP results for the three and twelve months ended December 31, 2008 and 2007.

The Company's balance sheet continues to be strong and includes $123 million in cash and cash equivalents.

Chief Executive Officer Joseph P. Caruso commented, "The downturn in the global economy continues to affect the aesthetic laser industry. The decrease in revenue across the sector has been swift and severe driven by the inability of many prospective customers to obtain financing and prompting others to delay their capital equipment purchases until economic conditions improve. We are responding to these challenging economic times by taking actions to reduce our cost structure to be more in line with current sales levels in all areas of the company, including reductions in headcount and operating expense. Our flexible business model enables us to lower expenses to respond to lower current revenue levels while still investing a higher than industry average on fundamental research and new product development. During the quarter, we were also able to balance sales price, volume and operating expenses which resulted in a close to breakeven bottom line and positive cash flows from operations."

Mr. Caruso continued, "We have built a diversified business model that does not rely solely on high-priced capital equipment sales. During the fourth quarter, 42% of our revenue was generated from sources not related to our capital equipment sales. These are volatile economic times, but we feel confident that we have the resources needed to navigate through them, continue as an industry leader, and when the economy recovers, emerge as a stronger company."

Use of Non-GAAP Financial Measures

To supplement Palomar's consolidated financial statements presented in accordance with GAAP, this news release uses the following measures defined as non-GAAP financial measures by the SEC: non-GAAP income before taxes, non-GAAP provision for income taxes, non-GAAP net income, and non-GAAP diluted earnings per share. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. In addition, the non-GAAP financial measures included in this news release may be different from, and therefore not comparable to, similar measures used by other companies. For more information on these non-GAAP financial measures, please see the non-GAAP data included below. This data has more details of the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures. Palomar's management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our core business operating results. Palomar believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing Palomar's performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Palomar's historical performance and our competitors' operating results. Palomar believes that these non-GAAP measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making.

Conference Call: As previously announced, Palomar will conduct a conference call and webcast today at 11:30 AM Eastern Time. Management will discuss financial results and strategic matters. If you would like to participate, please call (800) 597-0339 or listen to the webcast in the Investor Relations section of the Company's website at The telephone replay will be available one hour after the call at (888) 286-8010 passcode 52026952 and will be available for fourteen days. A webcast replay will also be available.

About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

For more information on Palomar and its products, visit Palomar's website at To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2007 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    Contacts:  Kayla Castle
               Investor Relations Manager
               Palomar Medical Technologies, Inc.

    Consolidated Statements of Income (Unaudited)

                             Three Months Ended       Twelve Months Ended
                                 December 31,              December 31,
                              2008         2007         2008          2007

      Product revenues    $13,260,047  $24,468,273  $69,378,948  $103,220,932
      Royalty revenues      2,225,921    2,421,193   10,520,132    13,005,459
      Funded product
       development revenues   484,451    1,263,563    2,434,395     6,698,063
      Other revenues        1,250,000            -    5,247,625       894,189
        Total revenues     17,220,419   28,153,029   87,581,100   123,818,643

    Costs and expenses:
      Cost of product
       Revenues             5,528,354    6,594,776   25,217,638    33,390,942
      Cost of royalty
       revenues               890,369      968,478    4,208,054     5,202,184
      Research and
       Development          3,539,604    4,430,197   17,692,888    16,673,191
      Selling and
       Marketing            4,968,017    6,279,118   23,339,759    24,885,695
      General and
       Administrative       3,231,927    5,839,838   20,516,522    17,495,400
        Total costs and
         Expenses          18,158,271   24,112,407   90,974,861    97,647,412

        (Loss) income
         from operations     (937,852)   4,040,622   (3,393,761)   26,171,231

        Interest income       594,268    1,597,468    3,652,324     6,398,805
        Other (expense)
         income              (255,641)     (11,642)    (316,805)      513,142

        (Loss) income
         before income
         taxes               (599,225)   5,626,448      (58,242)   33,083,178

      (Benefit) provision for
       income taxes          (179,109)   2,141,959        9,923    12,575,516

        Net (loss) income   $(420,116)  $3,484,489     $(68,165)  $20,507,662

    Net (loss) income
     per share:
      Basic                    $(0.02)       $0.19        $0.00         $1.12
      Diluted                  $(0.02)       $0.18        $0.00         $1.07

    Weighted average number
     of shares outstanding:
      Basic                18,087,847   18,295,748   18,160,700    18,277,324
      Diluted              18,087,847   18,960,555   18,160,700    19,254,023

    Non-GAAP data:
    (Loss) income before
     income taxes           $(599,225)  $5,626,448     $(58,242)  $33,083,178
      Royalty revenues:
       Back-owed royalty            -            -     (682,380)   (3,105,710)
      Other revenues: Trade
       dress infringement fees      -            -     (247,625)     (894,189)
      Cost of product
       revenues: Royalty
       adjustment                       (1,493,394)                  (662,636)
      Cost of royalty
       revenues: Back-owed
       royalty                      -            -      272,952     1,242,284
      General and administrative:
       Royalty settlement
       legal reimbursement          -            -            -      (227,355)
      General and administrative:
       Investment banking fee for
       international distributor
       agreement                    -            -    1,013,899             -
      FAS 123R stock-based
       Compensation           818,404      323,306    5,922,741       489,546
      Interest income:
       Interest on back-owed
       royalty                      -            -      (52,409)     (259,166)
    Non-GAAP income before
     income taxes             219,179    4,456,360    6,168,936    29,665,952

    (Benefit) provision for
     income taxes            (179,109)   2,141,959        9,923    12,575,516
      Provision for income
       taxes - non-cash       221,131   (1,804,372)     (12,282)  (10,590,525)
      Tax effect related
       to one-time
       events - cash          (33,145)     (70,205)     252,201      (205,034)
    Non-GAAP provision for
     income taxes               8,877      267,382      249,842     1,779,957

    Non-GAAP net income      $210,302   $4,188,978   $5,919,094   $27,885,995

    Non-GAAP diluted net
     income per share           $0.01        $0.22        $0.32         $1.45
    Diluted weighted
     average number of
     shares outstanding    18,246,401   18,960,555   18,406,357    19,254,023

    Consolidated Balance Sheets (Unaudited)

                                               December 31,   December 31,
                                                   2008          2007


      Current assets:
         Cash and cash equivalents             $122,601,139   $90,460,350
         Available-for-sale investments, at
          fair market value                               -    41,910,000
         Accounts receivable, net                 6,395,364    16,037,475
         Inventories                             16,045,725    12,896,154
         Deferred tax assets                      5,347,459     3,811,873
         Other current assets                       538,987     1,129,300
            Total current assets                150,928,674   166,245,152

      Marketable securities, at fair value        4,486,834             -

      Property and equipment, net                14,225,397     1,250,437

      Other assets                                    7,515       111,074

      Total assets                             $169,648,420  $167,606,663

                          Liabilities and Stockholders' Equity

         Note payable                            $6,000,000            $-
         Accounts payable                         3,247,051     1,987,579
         Accrued liabilities                      4,614,121    12,606,422
         Deferred revenue                         6,166,246     5,789,936
            Total current liabilities            20,027,418    20,383,937

         Deferred taxes                           2,815,577     2,533,220

            Total liabilities                   $22,842,995   $22,917,157

      Stockholders' equity:
         Preferred stock, $.01 par value-
            Authorized - 1,500,000 shares
            Issued - none                                 -             -
         Common stock, $.01 par value-
            Authorized - 45,000,000 shares
            Issued - 18,479,345 and
             18,442,846 shares, respectively        184,794       184,429
         Additional paid-in capital             205,306,957   199,988,081
         Accumulated other comprehensive
          (loss) income                            (542,443)       12,590
         Accumulated deficit                    (52,547,173)  (52,479,008)
         Treasury stock, at cost - 413,255
          and 105,000 shares, respectively       (5,596,710)   (3,016,586)
            Total stockholders' equity         $146,805,425  $144,689,506

      Total liabilities and stockholders'
       equity                                  $169,648,420  $167,606,663

SOURCE Palomar Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
2. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
5. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
6. Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008
7. Palomar Medical Reports Financial Results for Third Quarter 2008
8. Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
9. Reliant Technologies, and Palomar Medical Technologies, Announce Launch of a Fractional Technology Licensing Program
10. Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
11. MSU engineering team designs innovative medical device
Post Your Comments:
(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, ... 8th Day Software and Consulting, LLC , and named ... 8th Day Software, based in Tennessee , ... 8th Day expands EnvoyHealth,s service offerings for health care ... "In an interoperable ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at ...
Breaking Medicine Technology: